{"id":391477,"date":"2020-12-02T07:03:08","date_gmt":"2020-12-02T12:03:08","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=391477"},"modified":"2020-12-02T07:03:08","modified_gmt":"2020-12-02T12:03:08","slug":"amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\/","title":{"rendered":"Amicus Therapeutics Appoints Michael A. Kelly to its Board of Directors"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CRANBURY, N.J., Dec.  02, 2020  (GLOBE NEWSWIRE) &#8212; Amicus Therapeutics (Nasdaq: FOLD) today announced the election and appointment of Michael A. Kelly to its Board of Directors. Mr. Kelly is a proven leader with more than two decades of executive experience in the life sciences industry serving in various strategic finance and operations positions, including Chief Financial Officer and board member of multiple biotechnology companies.<\/p>\n<p align=\"justify\">John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, \u201cOn behalf of our Board of Directors, I am pleased to announce Michael Kelly\u2019s appointment to the Amicus Board. Michael\u2019s wealth of knowledge and experience managing and growing global, multi-product organizations in the biotech sector will be invaluable as we look toward the future and he will add much to our mission at Amicus for patients and for shareholders. Michael\u2019s appointment complements our existing strong group of directors and senior leaders as we continue to build one of the world\u2019s leading global biotechnology companies.\u201d<\/p>\n<p align=\"justify\">Currently, Mr. Kelly is President of Sentry Hill Partners, LLC, a global life sciences transformation and management consulting business, which he founded in 2018. He previously spent 14 years in senior and executive leadership positions with Amgen Inc., one of the world\u2019s largest biotechnology companies. Most recently, he was senior vice president of Amgen\u2019s Global Business Services division. Mr. Kelly twice served as Amgen\u2019s acting CFO. He also was vice president of multiple domestic and international business units. As vice president and CFO of Amgen\u2019s international commercial operations, Mr. Kelly developed and executed a strategy to expand the company\u2019s emerging markets footprint. From 2000 to 2003, Mr. Kelly was CFO of publicly traded TANOX, Inc. He also held financial leadership positions with BIOGEN, Inc., and NutraSweet Kelco Company, a subsidiary of Monsanto Life Sciences.<\/p>\n<p align=\"justify\">Mr. Kelly is an independent member of the board of directors for publicly traded Aprea Therapeutics, DMC Global, Inc., NeoGenomics, Inc., and Hookipa Pharma, Inc. In addition, he serves on the Council of Advisors and was the former audit committee chairman for Direct Relief, a humanitarian aid organization focused on health outcomes and disaster relief. Mr. Kelly received a Bachelor of Science degree in business administration from Florida A&amp;M University.<\/p>\n<p align=\"justify\">\u201cAmicus is at the forefront of science and innovation, with a unique dedication to people living with rare diseases. I am excited to be joining the Board at such an important time in the Company\u2019s growth and contributing on its path in becoming one of the world\u2019s leading biotechnology companies,\u201d said Mr. Kelly.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <u>About Amicus Therapeutics <\/u><br \/>\n        <\/strong><br \/>\n        <br \/>Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=v8VsBcTov723sjF2SsPWWL9eiCw08kSkNb9izDC-lo15iR2yyrxiZQl6hJL0dkXvJ1SVHyesd2smqb129mbSEA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.amicusrx.com<\/a>, and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mqO4kkf6QeKxzlAk2RboRl-uYiIrprfQaOiTOmTxhK4ZLgmKv-k9h9uz0kTlh9DX6cbjxW4wdwMn3UfXvPbhTg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Twitter<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uFXMWmAhqYBiEyhySAO8awROpUca4vG9Lce3ZQKr3AnBG_-gBW-uzU75UNPv-mW109XHYFhhVyRrJDeipDpKDJHgKud-O_ZJ7p_-Ms4WM1QO6NuVNhM2XOpqh7wm2CMF\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>CONTACT:<\/p>\n<p>\n        <strong>Investors: <\/strong><br \/>\n        <br \/>Amicus Therapeutics <br \/>Andrew Faughnan<br \/>Director, Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mr_-iwANCPH9EUzDXK-XWPsBq4kctZ6Jcn1dAr8dAA83tkD9zHypjXj7DiUYEUup7iaUmbcNdkUt0ZEbcD8mBmsBT7QhtxwxvX_rlBigW9s=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">afaughnan@amicusrx.com<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AJJNHjhkFG2wM4XxyVsdQnrQA91-I0uQEwJ3FX1Nl8UDYw0PLGod1a5TBNfjoR5QxsIMiatWmt__6NhbHmVJPQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/><\/a>(609) 662-3809<\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Amicus Therapeutics <br \/>Diana Moore <br \/>Head of Global Corporate Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AcCc0QASm2PqkJWufwMelV_ubYgnBVy725fOKdpMmuRwfBa5PWHKCKRjI2BWc2-9uTfW2NY_vltaCwGrqq0wPLar0asr0h8NXwHul_24oH0=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">dmoore@amicusrx.com<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pE-WJlPmkZu18g4zn8D2rFQdk4EVv4ktp2i9Gky_bD9CbFIsfRwwraaE0t3klchd\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/><\/a>(609) 662-5079<\/p>\n<p>FOLD\u2013G<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTA2MSMzODUxNzgwIzIwMDU2NTg=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/601543e3-20f6-46f0-9326-4ddd4caa9f62\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CRANBURY, N.J., Dec. 02, 2020 (GLOBE NEWSWIRE) &#8212; Amicus Therapeutics (Nasdaq: FOLD) today announced the election and appointment of Michael A. Kelly to its Board of Directors. Mr. Kelly is a proven leader with more than two decades of executive experience in the life sciences industry serving in various strategic finance and operations positions, including Chief Financial Officer and board member of multiple biotechnology companies. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, \u201cOn behalf of our Board of Directors, I am pleased to announce Michael Kelly\u2019s appointment to the Amicus Board. Michael\u2019s wealth of knowledge and experience managing and growing global, multi-product organizations in the biotech sector will be invaluable as we look toward &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Amicus Therapeutics Appoints Michael A. Kelly to its Board of Directors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-391477","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Amicus Therapeutics Appoints Michael A. Kelly to its Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amicus Therapeutics Appoints Michael A. Kelly to its Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CRANBURY, N.J., Dec. 02, 2020 (GLOBE NEWSWIRE) &#8212; Amicus Therapeutics (Nasdaq: FOLD) today announced the election and appointment of Michael A. Kelly to its Board of Directors. Mr. Kelly is a proven leader with more than two decades of executive experience in the life sciences industry serving in various strategic finance and operations positions, including Chief Financial Officer and board member of multiple biotechnology companies. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, \u201cOn behalf of our Board of Directors, I am pleased to announce Michael Kelly\u2019s appointment to the Amicus Board. Michael\u2019s wealth of knowledge and experience managing and growing global, multi-product organizations in the biotech sector will be invaluable as we look toward &hellip; Continue reading &quot;Amicus Therapeutics Appoints Michael A. Kelly to its Board of Directors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-02T12:03:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTA2MSMzODUxNzgwIzIwMDU2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Amicus Therapeutics Appoints Michael A. Kelly to its Board of Directors\",\"datePublished\":\"2020-12-02T12:03:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\\\/\"},\"wordCount\":540,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NTA2MSMzODUxNzgwIzIwMDU2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\\\/\",\"name\":\"Amicus Therapeutics Appoints Michael A. Kelly to its Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NTA2MSMzODUxNzgwIzIwMDU2NTg=\",\"datePublished\":\"2020-12-02T12:03:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NTA2MSMzODUxNzgwIzIwMDU2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NTA2MSMzODUxNzgwIzIwMDU2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amicus Therapeutics Appoints Michael A. Kelly to its Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amicus Therapeutics Appoints Michael A. Kelly to its Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Amicus Therapeutics Appoints Michael A. Kelly to its Board of Directors - Market Newsdesk","og_description":"CRANBURY, N.J., Dec. 02, 2020 (GLOBE NEWSWIRE) &#8212; Amicus Therapeutics (Nasdaq: FOLD) today announced the election and appointment of Michael A. Kelly to its Board of Directors. Mr. Kelly is a proven leader with more than two decades of executive experience in the life sciences industry serving in various strategic finance and operations positions, including Chief Financial Officer and board member of multiple biotechnology companies. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, \u201cOn behalf of our Board of Directors, I am pleased to announce Michael Kelly\u2019s appointment to the Amicus Board. Michael\u2019s wealth of knowledge and experience managing and growing global, multi-product organizations in the biotech sector will be invaluable as we look toward &hellip; Continue reading \"Amicus Therapeutics Appoints Michael A. Kelly to its Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-02T12:03:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTA2MSMzODUxNzgwIzIwMDU2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Amicus Therapeutics Appoints Michael A. Kelly to its Board of Directors","datePublished":"2020-12-02T12:03:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\/"},"wordCount":540,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTA2MSMzODUxNzgwIzIwMDU2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\/","name":"Amicus Therapeutics Appoints Michael A. Kelly to its Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTA2MSMzODUxNzgwIzIwMDU2NTg=","datePublished":"2020-12-02T12:03:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTA2MSMzODUxNzgwIzIwMDU2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTA2MSMzODUxNzgwIzIwMDU2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amicus-therapeutics-appoints-michael-a-kelly-to-its-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Amicus Therapeutics Appoints Michael A. Kelly to its Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/391477","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=391477"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/391477\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=391477"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=391477"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=391477"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}